Osteoarthritis (OA) is a common health problem with symptoms including reduced functioning and joint pain. Protracted pharmacological management of knee OA is associated with side effects including gastrointestinal, renal, and neurological dysfunction.
Background
Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of pain and disability worldwide. 1 OA affects more than 27 million Americans, 2 with the knee, joint, hip, and wrist the most common sites affected by OA. A recent study estimated that approximately half of all adults will develop symptomatic knee OA by the age of 85 years. 3 Loss of joint function because of OA is a major cause of work disability and reduces quality of life. The Centers for Disease Control and Prevention estimates that OA and related arthritic conditions cost the US economy nearly $81 billion per year in direct medical care. Characteristics of knee OA include a reduced ability to complete functional tasks, decreases in knee strength, decreased knee range of motion, and joint pain. 4 Knee OA pain is commonly managed pharmacologically with analgesics particularly nonsteroidal anti-infl ammatory drugs, in an attempt to preserve the patient's ability to complete functional tasks. Protracted oral pharmacological management of knee OA is associated with signifi cant side effects, resulting in gastrointestinal, renal, and neurological dysfunction. 5 , 6 Menthol is used as an active ingredient in many topical ointments and pain-relieving gels such as Biofreeze, Icyhot, and BenGay. 7 -9 Menthol is well known for its ability to elicit cold sensations. It also has antinociceptive and counterirritant properties. 8 , 10 , 11 Topically applied gels that contain menthol result in feelings of cold by stimulating the transient receptor potential family of ion channels or (TRPs). TRPs are found throughout the body, but Transient receptor potential cation channel subfamily M member 8 (TRPM8) is found mainly within thermosensitive neurons, which in addition to responding to reductions in temperature also fi re in response to menthol. 7 , 12 -16 TRPM8 serves as a neuronal sensor of cold temperatures and is essential for innocuous cool and noxious cold sensations. 17 , 18 Calcium-imaging techniques have demonstrated that application of menthol to cloned TRPM8 cells results in a heavy intracellular infl ux of calcium ions, causing depolarization due to the opening of nonselective calcium permeable cation channels. 7 , 12 -16 This increase in sensitization of the thermosensitive neurons is what leads to the perceptions of coolness with topical menthol application. Stimulation of these thermosensitive neurons is also associated with the analgesic effect of topical menthol gels. Afferent thermosensitive neurons that are stimulated by moderate cooling or the application of menthol have been found to have an inhibitory effect on the nociceptive afferent neurons and on the dorsal-horn neurons, which conduct pain impulses to the thalamus. 19 This analgesic effect of menthol was demonstrated in vitro by Haeseler et al. 20 when studying the effect of an electrical stimulus applied to human skeletal muscle tissue after the tissue was exposed to menthol. At various application strengths, inactivated sodium channels were measured to determine the effect on depolarization. It was demonstrated that the menthol blocked the alpha subunit of voltage-gated sodium channels, therefore causing hyperpolarization of the nervous membrane and a block in the signal of pain transduction. This study demonstrated that the application of menthol can have an analgesic effect through exerting an inhibitory gate control over nociceptive inputs. There are no studies, to date, which have examined the effect of a topically applied menthol gel on the performance of functional tasks and knee pain among patients with OA. The purpose of this study was to compare the ability to complete functional tasks and knee pain while completing functional tasks among knee OA patients after topical application of either 3.5% menthol gel or an inert placebo gel. This purpose was addressed by testing the following hypothesis: (H1) The application of 3.5% menthol to the affected osteoarthritic knee joint will result in improved performance of functional tasks compared to the application of a placebo control. (H2) The application of 3.5% menthol to the affected osteoarthritic knee joint will result in reduced pain while performing functional tasks compared to the application of a placebo control.
METHODS
A convenience sample of 20 individuals previously diagnosed with unilateral or bilateral OA of the knee were recruited from the community through notices placed in local newsletters and electronic mailings. A sample size of 20 was considered adequate to detect an effect size of 0.6 in functioning and pain following administration of the menthol and a 0.8-effect size when comparing functioning and pain between the menthol and the placebo. These anticipated effect sizes are consistent with previous authors who have reported the pain-relieving effect of glucosamine sulfate and nonsteroidal anti-infl ammatory drugs 21 and ice therapy 22 in treating OA. Inclusion criteria were subjects 40 years or older, with a previous diagnosis of knee OA made by a physician, consuming daily scheduled dosages of oral medication to relieve their knee pain, and able to complete a simple battery of functional tasks. Exclusion criteria comprised the exercise-testing exclusion criteria outlined by the ACSM, 23 inability to travel to the testing site and/or the inability to read and write English at an eighth-grade level. Interested individuals were instructed to contact a member of the research team by phone to complete a brief telephone screen and to schedule an initial appointment to provide written informed consent and to complete data collection procedures. This telephone screening verifi ed the presence of inclusion criteria and the absence of the exclusion criteria. If subjects did not meet any of the exclusion criteria during this telephone screening, they were scheduled for two separate visits to the physical therapy laboratory with each of these visits separated by at least 7 days. During the initial visit, prior to any data collection taking place, subjects provided written consent using a form approved by the university's institutional review board. Subjects then completed a brief demographic questionnaire, which queried age, gender, height, and weight, which was collected at the fi rst of the two visits to the laboratory. The Western Ontario and McMaster Universities Arthritis (WOMAC) index was also collected upon the subject's arrival at the laboratory at both testing sessions prior to any functional tasks being assessed. The WOMAC index is a self-administered tool that yields a score for three dimensions specifi c to knee OA: pain, stiffness, and physical functioning. Each item on the pain, stiffness, and functional subscales of the WOMAC index requires the subject to respond on a 5-point Likert scale regarding the construct within the last week. Previous authors have established the reliability and validity of this instrument among knee OA patients. 24 -27 All subjects underwent the same data collection protocol at the same time of day at each of their two laboratory visits. Subjects were instructed to consume their prescribed dose of pain medication at the same prescribed time on both data collection days. Once subjects arrived at the laboratory, they completed fi ve functional tasks in the following order; 6-Minute Walk (6-MW), Timed Get Up and Go (TUG), a number of sit to stand repetitions in 30 seconds (timed chair stands), duration of time required to ascend 13 stairs (Up stairs) and descend 13 stairs (Down stairs). Immediately following completion of each of these tasks, subjects were asked to provide a rating of the pain they experienced during the performance of the task in the knee affected by OA. If both knees were affected, they were asked to report the pain in the more painful of their knees. Following these assessments, one of two randomly selected topical gels was applied to the subject's affected knee and the assessments of performing the functional tasks and
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pain were again conducted. Subjects were provided with approximately 5 minutes of rest between the initial and second assessment during each visit to the laboratory. A blocking technique was used to randomly assign subjects to receive the menthol or placebo at their initial visit to obtain an even numbers of subjects who received the menthol or placebo at the initial visit. This blocking technique involved each subject selecting one of 20 envelopes inside of which was a card that indicated their initial treatment was either "A" or "B." The 10 envelopes containing a card with "A" indicated the subject received the menthol treatment on their initial visit and the placebo at their second visit. The 10 envelopes containing a card with a "B" indicated the subject initially received the placebo and then received the menthol treatment at their second visit. At 7 days following the initial visit to the laboratory at the same time of day, the alternative gel was applied in the same manner as the fi rst one.
Functional Tasks
Each subject's ability to complete functional tasks was assessed while they performed 5 standard activities including a 6-MW , sit-to-stand in 30 seconds, TUG, and time required to ascend/descend a fl ight of 13 stairs). These assessments were performed by the same research staff at the same laboratory over the duration of the study.
The Six minute walk time (6-MWT) is a performancebased test originally developed to assess exercise tolerance in patients with pulmonary disease 28 with the distance walked in 6 minutes measured and recorded, with a greater distance indicating better functional ability. The 6-MWT has been used previously in other patient populations and as a standard measure of functional mobility in older adults and patients following lower extremity joint arthroplasty. 27 , 29 -33 During each of the two data collection visits to the laboratory immediately following completion of the WOMAC index, the participants completed the 6-MWT. If a participant was currently using an assistive device for ambulation, they were permitted and encouraged to use the device during the test. Each participant was instructed to "walk as fast and as safely as possible, to cover as much ground as possible" for 6 minutes while walking around a 30-meter indoor course marked off in 1-meter increments. Encouragement during this assessment was minimal, and participants were instructed to stop at any point if they experienced pain or fatigue and to resume walking once they were ready. Participants were notifi ed at the end of the third and fi fth minute to provide information on time remaining for completing the task. The total distance walked in 6 minutes was recorded to the nearest meter.
The TUG test was originally designed as a functional task used to measure basic mobility, balance, and locomotor performance in older adults with balance disturbances. 34 , 35 The TUG test has been used in many different patient groups including individuals with rheumatoid arthritis, OA, and with patients after total knee replacement and has been shown to be reliable and responsive. 35 -43 Following the 6-MWT and a 2 to 3 minute rest period, the participants performed the TUG test as described by Podsiadlo and Richardson. 35 The TUG test began with the participant in a standard armless chair (45-cm seat height) with both feet fl at on the fl oor. If a participant was currently using an assistive device for ambulation, they were permitted and encouraged to use it for this assessment. The use of an assistive device has been shown to have a signifi cant impact on the performance and score on the TUG test. 44 The TUG test was demonstrated to the participant, and they were instructed to perform the test as "quickly and safely as possible." On the command "go," the participant rose from the chair, walked around a small cone placed 3 meters from the edge of the front of the chair, returned to the chair, and sat down. Participants performed 3 trials, and the fastest time to the nearest 0.1 second was recorded by a stopwatch.
The TCS test involves the number of sit-to-stand repetitions an individual can complete in 30 seconds, with a higher number of repetitions completed indicating a better performance. 45 Normative age-referenced values for males and females for the 30-second TCS test have been published by Rikli and Jones. 45 The same standardized armless chair (45-cm seat height) used previously for the TUG test was also used for the TCS test. From a seated starting position, participants were instructed at the word "go" to "stand up completely and sit down safely and as quickly as you can, as many times as you are able in 30 seconds." The score recorded was the number of complete sit-to-standing repetitions performed, disregarding any partially completed repetitions.
Ascending (Up stairs) and descending (Down stairs) have also been reported by previous authors as valid methods of assessing functional ability among patients with knee OA. 38 , 40 , 46 Evaluation of the performance of ascending and descending stairs has also been shown to be reliable and valid tests of function in patients following total knee replacement. 47 The relevance of assessing ascending and descending stairs as independent tasks has been suggested as differences in performing these tasks separately may reveal important clinical and functional correlates with other impairments in older adults. 48 For example, diffi culty in ascending stairs has been associated with the presence of hypertension, arthritis, and symptoms of depression, as well as poor balance, and decreased grip strength, whereas diffi culty in descending stairs has been associated with a higher frequency of activities of daily living) limitations such as bathing, dressing, and walking inside the house. 48 Following completion of the TCS test, the participants were instructed to ascend (Up Stairs) and then descend (Down Stairs) a fl ight of 13 stairs. Handrails were located on both sides of the fl ight of stairs (rise ϭ 20 cm and tread ϭ 27 cm). The assessment began with the participant facing the stairs with their hands at their sides standing with both feet on the fl oor. Participants were instructed and encouraged to use the handrails if needed to maintain balance and safety. At the word "go," the time to ascend, and then descend, was recorded separately to the nearest 0.01 second with a stopwatch. The time started when the participant's foot was lifted initially from the fl oor and stopped when both feet arrived on the fi nal stair/landing.
Pain was measured immediately following completion of each functional task by asking subjects to rate the pain in their knees on a 100-mm visual analog scale (VAS). TheVAS is considered by many to be one of the most clinically useful, valid, and reliable methods of assessing pain intensity 49 -51 and has been reported to provide greater sensitivity than a numerical pain scale. 51 Pain was assessed immediately at completion of each of the functional performance tasks (eg, 6-MWT, TUG, TCS, Up Stairs, and Down Stairs) as indicated by a small vertical mark made by the participant on a 100-mm VAS anchored at one end "no pain" and the other "extreme pain." This resulted in a pain score while performing each of the functional tasks ranging from 0 to 100. The VAS has been demonstrated to correlate well with other measures of pain and exhibit good reliability. 53 
Interventions
During each laboratory session following initial assessment of the subject's functional ability and pain, one of two randomly selected topical gels was applied to the subject's affected knee. These gels were applied within 5 minutes of completing the initial assessment and immediately prior to the subject beginning their second assessment. The dose of both of these gels was 5 mL, which is consistent with previous studies who reported a treatment effect for menthol containing topical gels (1 mL of gel for every 200 cm 2 of surface area). 54 -56 The treatment condition selected at the particular laboratory session was applied by a gloved technician to the anterior and posterior knee from the superior patella to the quadriceps insertion over a time period of approximately 5 seconds. The experimental treatment condition consisted of 3.5% menthol (Biofreeze). The placebo treatment consisted of KY jelly, which contains no neuroactive agents, primarily water, glycerin, and gluconolactone.
Analysis
Descriptive analysis was conducted on all of the variables collected to determine the appropriateness of parametric statistics. Once the assumptions of conducting parametric statistics were verifi ed repeated measures ANOVA with time (preapplication vs postapplication) treatment condition (menthol vs placebo), and interaction (time by treatment) were calculated to address the study hypotheses. These statistics employed the measures of the ability to complete functional tasks and knee pain while completing functional tasks as separate dependent variables.
Signifi cant ( P Ͻ .05) main effects were further explored through Bonferroni post hoc comparisons to determine the specifi c differences between means within and between the treatment conditions.
RESULTS
Descriptive statistics of the subject's demographic characteristics (see Table 1 ) indicated that the sample represented middle-aged, primarily female, overweight patients with knee OA. The subject's performance of the functional tasks was consistent with previous groups of patients with knee OA. 26 , 57 Analysis of the subject's responses on the WOMAC index indicated both groups were experiencing a mild degree of pain, stiffness, and functional impairments during the study. These responses on the WOMAC index indicate the sample reported a similar amount of pain, stiffness, and functional disability due to their knee OA as previous samples of independent community-residing knee OA patients who were not contemplating surgical intervention. 25 , 26 t -test comparisons indicated that the subjects did not report statistically different scores on their WOMAC index prior to either of their two data collection sessions in the laboratory (see Table 2 ).
Repeated measures ANOVA indicated no signifi cant between-group differences or time by treatment interaction in performance of any of the functional tasks at any of the data collection time points. The analysis also indicated a signifi cant time effect on the performance of 6-MW ( F ϭ 11.39, P ϭ .00), TCS (F ϭ 20.99, P ϭ .00), and Down stair ( F ϭ 6.61, P ϭ .01), functional tasks between the pre-and postapplication time points. Post hoc analysis indicated that performance of the 6-MW, TCS, and Down stairs signifi cantly improved as a result of applying the 3.5% menthol gel. This same post hoc analysis indicated that the placebo treatment resulted in improved performance of the Down stairs task only (see Table 3 ). Signifi cant treatment effect sizes (partial eta square p 2) 58 ranged from medium ( p 2 ϭ 0.090) on the Stair up task to large ( p 2 ϭ 0.36) for the TCS task.
The analysis indicated no signifi cant between-group differences or time by treatment interaction in pain while performing any of the functional tasks at any of the data collection time points. The analysis also indicated a 
DISCUSSION
These fi ndings do not support the study hypotheses that a 3.5% menthol gel applied to an osteoarthritic knee joint will result in improved performance of functional tasks or pain while performing functional tasks compared to the application of a placebo control. The signifi cant improvements in functioning and pain as a result of the menthol treatment appear to indicate further discussion. The application of 3.5% menthol to the affected osteoarthritic knee joint resulted in improved performance of 3 of 5 functional tasks, whereas the placebo improved the performance of only 1 of the 5 functional tasks assessed. As well, the application of 3.5% menthol resulted in signifi cantly less pain while performing 4 of the 5 functional tasks, whereas the placebo condition did not signifi cantly change the subject's pain while performing any of the functional tasks. These promising fi ndings must be tempered by the result that performance of functional tasks and pain was not signifi cantly different following application of the menthol or the placebo conditions. These promising fi ndings may be attributable to a number of factors. By selecting a sample who was functioning at a relatively high level, the effect of the intervention may not of had the potential to substantially improve their functioning or decrease their pain. That is a ceiling effect may have confounded the fi ndings. Another explanation may be that the intervention was not able to produce results beyond the placebo effect of the control condition. Hróbjartsson and Gøtzsche 59 in their Cochrane Review reported in their study of more than 200 trials that placebo interventions were not found to have important clinical effects in general but may infl uence patient-reported pain, although it was "diffi cult to distinguish patient-reported effects of placebo from response bias." These authors reported the pooled relative effect for a placebo to be 0.93 (effect of only 7%) but signifi cant. The fi ndings of this study seem to be consistent with what these authors would anticipate to be the effect the placebo effect on patient reports of pain (mean change in pain with the placebo ϭ 12.8%). The observed difference in pain resulting from the menthol treatment observed in this trial appears clinically meaningful (mean change in pain with the menthol ϭ 33.8%) and is perhaps attributable to the menthol intervention.
Although statistically signifi cant the improvement in functioning observed in this study as a result of the menthol intervention may not meet the threshold for clinical signifi cance. Previous authors have established a threshold for clinically signifi cant difference of the 6-MWT to be 25-54 meters 60 , 61 The statistically signifi cant improvement in the 6-MWT as a result of the menthol did not appear to reach this threshold. Although there is no similar threshold established for TCS and the Down stairs tasks, the clinical importance of 7.42% and 8.66% improvements in these tasks, respectively, as a result of the menthol is debatable. Another possible explanation for the signifi cant improvement in the 6-MWT and the TCS test under the menthol condition was that the subjects could easily gauge their performance on these functional tasks (distance walked and repetitions performed) whereas the other functional tasks were timed, and their performance was not disclosed to them by the research staff conducting the assessments. Since the menthol gel has a distinct odor and produces a cooling or "tingling" sensation when applied topically, it was likely that the subjects were aware of which condition contained the menthol content. With this knowledge, subjects may have attempted to increase their performance on the 6-MWT and TCS following application of the menthol treatment. Future researchers conducting similar studies may wish to assess the effect of topical menthol in such a way that the subjects cannot detect the content of the menthol in the gel. The declines in pain during the functional tasks appear to be clinically signifi cant ranging from 27% to 37% decline in pain following the application of the menthol treatment. These observed decreases in pain with the application of the menthol are consistent with the fi ndings of previous investigators who have reported that afferent thermosensitive neurons are stimulated by menthol, 7 , 12 -16 which in turn inhibit or block the nociceptive afferent neurons, which conduct pain impulses. 19 This proposed analgesic mechanism of menthol is validated by the results of this study and is consistent with the fi ndings of Gaudioso et al. 62 who reported that low concentrations of menthol cause analgesia in mice, blocking pain voltage-gated Na ϩ channels in dorsal root ganglion. These authors concluded that menthol is a state-selective blocker of Na ϩ of nociceptive afferent neurons channels and may have utility as a topical analgesic compound. Thus, the analgesic effects of menthol observed in this study are consistent with the biochemical mechanism of action observed in previous studies and support anecdotal reports that the topical application of menthol produces an analgesic effect.
The results of this study must be interpreted cautiously for a number of reasons. First, neither the researcher nor the subjects were blinded to the treatment conditions or the purposes of the study. This lack of blinding may have resulted in an expectation bias or the Hawthorne effect from both the subject and the researcher collecting the data. Second, the sample was consuming daily dosages of pain-relieving medications, which may have contaminated the fi ndings. The research team considered purposely evoking pain within the sample by asking the subjects not to take their pain medication on the data collection days to be unethical. To minimize the effect of subjects taking their pain medication, they were instructed to take their scheduled pain medications at the same time of day on the days when data were collected and data were collected at the same time of day from each individual subject. This approach maintained the consistency of any effect of the subject's consumption of pain medication on the outcome variables over the data collection points. Furthermore, the results of the WOMAC pain subscale and the functional tasks indicated that the subjects were in mild pain over the previous week with high levels of functional ability similar to previously studied groups of patients with knee OA. These fi nding may indicate a ceiling effect that any treatment may not be able to reduce the subject's pain or improve their functioning because they were experiencing only mild levels of pain in the previous week and were functioning at a high level. It is interesting to observe that the topical menthol condition resulted in signifi cant reductions in pain in addition to the subject's scheduled pain medications. This additive analgesic effect of topical menthol with the subject's scheduled pain medications supports the validity of the "complimentary" effect of topical menthol to relieve pain. This observation suggests that the analgesic mechanism of action is different between menthol and oral pain medications subjects in this study were consuming and indicates further study in the area. These results provide only the immediate effects of the intervention and clinical applicability to situations where an immediate pain-relieving response is indicated. This immediate analgesic effect may be desirable prior to pain-evoking treatments including maintaining fl exibility or strength of the affected knee joint.
The fi nal limitation of the study was that the repeatedmeasures nature of the design may have resulted in a familiarization effect with the data collection protocol. Subjects may have performed differently on the functional tasks and had different pain during their second visit to the laboratory based upon becoming familiar with the data collection protocol during their fi rst visit to the laboratory. The impact of this familiarization effect was minimized 
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by randomly assigning the ordering of the menthol and placebo conditions during the fi rst visit to the laboratory and evaluating subjects while they performed familiar functional tasks. The repeated measures design was also selected to minimize wide anticipated differences between knee OA patients on their functional ability and pain previously reported in the literature. 63 If the small sample in this study were randomized to receive either only a treatment or a control condition, the wide variability in functioning and pain exhibited by knee OA patients may have diluted the statistical power of the fi ndings. Future randomized clinical trials may wish to directly compare the effects of the topical menthol and a placebo control among large randomly assigned groups of knee OA patients to minimize the effect of variability.
The results of this preliminary study may indicate the effi cacy of topical menthol to improve the functioning and decrease the pain among knee OA patients. These fi ndings are consistent with previous investigators who have proposed a biochemical mechanism of action for topical menthol as an analgesic. This consistent evidence regarding the effectiveness of topical menthol to relieve pain provides the clinician with another approach to treating pain among knee OA patients. Standard treatment of knee OA pain includes nonsteroidal anti-infl ammatory drugs, which are accompanied by signifi cant gastrointestinal, renal, and neurological side effects. 6 Using topical menthol to compliment standard pharmacological treatment of knee OA may contribute to enhance pain relief and improve functional ability particularly during pain-evoking activities. Further study is needed to determine how long the pain-impacting effect of the menthol lasts and to provide more insights into the extent to which its effectiveness represents more than a placebo effect.
